Extensively Drug-Resistant Tuberculosis: Clinical Trials

9 trials for Extensively Drug-Resistant Tuberculosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 unknown. 9 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 39Completed 8, Unknown 1
Phase 24Completed 3, Unknown 1

Follow Extensively Drug-Resistant Tuberculosis: new trials by email Literature Review of Extensively Drug-Resistant Tuberculosis trials Research Report on Extensively Drug-Resistant Tuberculosis

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Economic Evaluation of New MDR TB Regimens
Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3CompletedMedecins Sans Frontieres, Netherlands732020-10-202024-04-22
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Bedaquiline 100 MG, Delamanid 50 MG Oral Tablet, Clofazimine 100 MG Oral Capsule - Tuberculosis, Multidrug-Resistant, Tuberculosis
Phase 3CompletedMédecins Sans Frontières, France3232020-04-062025-02-10
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
Bedaquiline Oral Tablet, Linezolid Oral Tablet, Delamanid in Oral Dosage Form - Tuberculosis, Pre-XDR-TB
Phase 3CompletedWits Health Consortium (Pty) Ltd4022019-08-222024-08-28
PRACTECAL-PKPD Sub Study
Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3UnknownMedecins Sans Frontieres, Netherlands2402019-08-062021-05-14
Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis
Pretomanid, Linezolid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Phase 3CompletedGlobal Alliance for TB Drug Development1812017-11-212023-06-29
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
Bedaquiline, Pretomanid, Moxifloxacin - Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3CompletedMedecins Sans Frontieres, Netherlands5522017-01-012024-05-01
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
Linezolid, Bedaquiline, Levofloxacin - Tuberculosis, Multidrug Resistant Tuberculosis
Phase 2 / Phase 3CompletedUniversity of Cape Town1542015-11-122021-09-29
A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
Bedaquiline, PA-824, Linezolid - Pulmonary Tuberculosis
Phase 3CompletedGlobal Alliance for TB Drug Development1092015-03-012025-09-08
Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV
Immunoxel, Placebo - Tuberculosis, HIV
Phase 3CompletedLisichansk Regional Tuberculosis Dispensary2692010-01-012015-05-20

Narrower conditions

Tuberculosis, Multidrug-Resistant (9)  ·  Tuberculosis (6)  ·  Tuberculosis, Pulmonary (6)  ·  Bacterial Infections (1)  ·  Gram-Positive Bacterial Infections (1)  ·  Mycobacterium Infections (1)

Broader conditions

Actinomycetales Infections (9)  ·  Bacterial Infections and Mycoses (9)  ·  Infections (9)  ·  Bacterial Infections (8)  ·  Gram-Positive Bacterial Infections (8)  ·  Mycobacterium Infections (8)  ·  Lung Diseases (6)  ·  Respiratory Tract Diseases (6)  ·  Respiratory Tract Infections (6)  ·  Tuberculosis (3)

Interventions

Linezolid (8)  ·  bedaquiline (8)  ·  Clofazimine (5)  ·  pretomanid (5)  ·  Moxifloxacin (4)  ·  Levofloxacin (2)  ·  OPC-67683 (2)  ·  Dosage Forms (1)  ·  Ethionamide (1)  ·  Isoniazid (1)  ·  Kanamycin (1)  ·  Pyrazinamide (1)  ·  Tablets (1)  ·  terizidone (1)

Sponsors

Medecins Sans Frontieres, Netherlands (3)  ·  Global Alliance for TB Drug Development (2)  ·  Lisichansk Regional Tuberculosis Dispensary (1)  ·  Médecins Sans Frontières, France (1)  ·  University of Cape Town (1)  ·  Wits Health Consortium (Pty) Ltd (1)

Countries

South Africa (7)  ·  Belarus (3)  ·  Uzbekistan (2)  ·  Georgia (1)  ·  India (1)  ·  Kazakhstan (1)  ·  Lesotho (1)  ·  Moldova (1)  ·  Mongolia (1)  ·  Pakistan (1)  ·  Peru (1)  ·  Russia (1)  ·  Ukraine (1)  ·  Vietnam (1)

Top investigators

Bern Nyang'wa, MB BS, MPH (1)  ·  Bern-Thomas Nyang'wa, MD (1)  ·  Carole Mitnick, Sc.D (1)  ·  Francesca Conradie (1)  ·  Francesca Conradie, MD (1)  ·  Francesca M Conradie (1)  ·  Keertan Dheda, MBChB (1)  ·  Lorenzo Guglielmetti, MD (1)  ·  Morounfolu Olugbosi, MD (1)  ·  Sedona Sweeny (1)

Results publications

PMID 22397570, PMID 22401633, PMID 27868466, PMID 31932382, PMID 32130813, PMID 34489274, PMID 34604901, PMID 35175905, PMID 35698158, PMID 36053506, PMID 36546625, PMID 36804834, PMID 37980911, PMID 38037119, PMID 38842323, PMID 40683298, PMID 41917253, PMID 42270675, PMID 42341301, PMID 42429813